Related Experiment Video
Updated: Jul 19, 2026
08:14
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
Published on: October 26, 2018
Future perspectives for the development of P-glycoprotein modulators.
1National Cancer Institute, National Institutes of Health, Medicine Branch, Bethesda, MD 20892, USA.
Summary
Multidrug resistance in cancer, often caused by P-glycoprotein (Pgp) efflux, remains a challenge. Clinical trials show Pgp modulation
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemotherapeutic resistance is a major hurdle in cancer treatment.
- P-glycoprotein (Pgp) mediated drug efflux is a key mechanism of multidrug resistance.
- In vitro studies showed Pgp inhibitors could overcome this resistance.
Purpose of the Study:
- To evaluate the clinical efficacy of P-glycoprotein modulators in cancer treatment.
- To understand the challenges and insights gained from clinical trials on Pgp modulation.
- To lay the foundation for future research on Pgp and drug resistance.
Main Methods:
- Clinical trials involving P-glycoprotein modulators.
- Basic research on drug resistance mechanisms.
- Analysis of clinical trial data and basic science findings.
Main Results:
- Clinical trials of Pgp modulators have not definitively resolved their value in cancer treatment.
- Initial trials provided insights into the difficulties of conducting such studies.
- Continued basic research offers a strong foundation for future investigations.
Conclusions:
- The clinical utility of P-glycoprotein modulation in cancer therapy is still under investigation.
- Understanding transporter roles and developing novel modulators are crucial for overcoming drug resistance.
- Future research should leverage clinical and basic science insights to advance Pgp modulation strategies.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...